Browse Clinical Publication Articles by Topic

Safety of Infliximab After Live Vaccines

Despite concerns about the use of infliximab for children with Kawasaki disease shortly after administration of live vaccines, retrospective reviews do not show any vaccine-related infections following subsequent infliximab use.

Doxycycline Plus a Beta-Lactam for Treatment of Inpatients with Community-Acquired Pneumonia

In this retrospective study of an elderly male population hospitalized with community-acquired pneumonia, the combination of doxycycline with a beta-lactam was at least as effective as a respiratory fluoroquinolone or a combination of a beta-lactam with azithromycin.

Cellular Tests Are Not Accurate for Diagnosing Lyme Disease

A prospective case-control study from the Netherlands evaluated three cellular tests for diagnosing Lyme disease. All three had low specificity compared to serological testing, leading to an unacceptably high number of false-positive results.

Boosting with the New Bivalent COVID-19 Vaccines

The Centers for Disease Control and Prevention has made recommendations for the use of the newly approved bivalent COVID-19 booster vaccine.

Antibiotic Resistance: We Were Doing Great and then COVID Happened

After improvement, antimicrobial resistance in the United States significantly increased.

Importance of Discordant Grading of Moderate Aortic Stenosis

A study of patients with moderate aortic stenosis by Doppler echocardiographic calculated valve area revealed 40% exhibit discordant measures, where pressure gradient is lower than expected. These patients died more often than those with concordant measurements, especially those where the discrepancy was caused by low flow.

Statins Plus Ezetimibe vs. Statins Alone

A comparison of rosuvastatin 10 mg/day plus ezetimibe (10 mg/day) to 20 mg/day of rosuvastatin alone showed non-inferiority in three-year major cardiovascular outcomes, with lower LDL cholesterol levels and fewer episodes of drug discontinuation or dose reductions in the combination therapy group.

REVIVED Shows No PCI Benefit for Patients with Coronary Disease, Reduced EF

Researchers randomly assigned patients with an ejection fraction ≤ 35% and severe coronary disease to percutaneous coronary intervention or optimal medical therapy alone. After 3.4 years median follow-up, researchers noted no significant differences between groups in terms of all-cause death or heart failure hospitalization.

Hot Trials from the European Society of Cardiology Annual Congress

Below are some highlights from four key studies presented in Barcelona, Spain, between Aug. 26 and Aug. 29, 2022, along with Dr. Crawford’s personal commentary on each.

Betibeglogene Autotemcel Suspension (Zynteglo)

The FDA has approved the first cell-based gene therapy to treat adult and pediatric patients with beta-thalassemia who require regular blood transfusions.